IP Library Granted Patent US 8,748,580
Granted Patent B2
US 8,748,580 · App. 13/077,347 · Granted Jun 10, 2014

Device for enhancing immunostimulatory capabilities of T-cells

Inventor: Michael Har-Noy (Jerusalem, IL)
Assignee: Immunovative Therapies, Ltd.
C12N5/0636C12N2533/40C12N2501/40A61K2039/57A61K2039/5154C12N2501/51C12N2501/23C12N2531/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,748,580
App. No.
13/077,347
Granted
Jun 10, 2014
Kind
B2
Abstract

T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.

Claims (15)

1. A device for enhancing immunostimulatory capabilities of T-cells comprising:

an universal crosslinking agent comprising a support coated with a first material, wherein the first material is capable of crosslinking more than one array of second materials, the second materials capable of binding moieties on the surface of T-cells to deliver a signal to the T-cells and wherein each successive array of second materials is added at a later time in the T-cell response than the previous array of second materials and wherein the second materials comprise anti-chemokine receptors.

2. The device of claim 1 wherein each of the one or more arrays comprises one or more second materials.

3. The device of claim 1 wherein each of the one or more arrays comprises two or more second materials.

4. The device of claim 1 wherein the universal crosslinking agent is capable of crosslinking second materials bound to the T-cell surface moieties.

5. The device of claim 1 wherein an array of second materials comprises one or more antibodies that have specificity to a T-cell surface moiety.

6. The device of claim 1 wherein the first material is an antibody.

7. The device of claim 1 wherein the support is a biodegradable support.

8. The device of claim 1 wherein the support is a biodegradable microsphere.

9. The device of claim 1 wherein the support is biodegradable into a substance that is nontoxic to humans.

10. The device of claim 1 wherein the support is a microsphere that degrades in 14 days or less.

11. The device of claim 1 wherein the anti-chemokine receptors are in the C—C and C—X—C categories.

12. The device of claim 11 wherein the anti-chemokine receptors are selected from CCR1, CCR2, CCR3, CCR4, CCR5 and CXCR3.

13. The device of claim 1 wherein the first material crosslinks at least two arrays of second materials, each array comprising at least two second materials and wherein the second array is added at a later time in the T-cell response than the first array.

14. The device of claim 1 wherein the first material crosslinks more than two arrays of second materials, each array comprising at least two second materials and wherein each successive array is added at a later time in the T-cell response than the previous array.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ADDRESS OS THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 050489 FRAME: 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 28, 2020
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 052915/0513 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME FROM IMMUNOVATIVE THERAPIES, LTD. TO MICHAEL HAR-NOY ON THE ORIGINAL COVER SHEET PREVIOUSLY RECORDED ON REEL 050489 FRAME 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 2, 2019
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050610/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: IMMUNOVATIVE THERAPIES, LTD.
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050489/0245 →
RESCISSION Recorded Sep 12, 2019
From: HAR-NOY, MICHAEL
To: HAR-NOY, MICHAEL
Reel/Frame 050467/0081 →
Continuity (4)
Division 12687281 · Jan 14, 2010
Division 11066133 · Feb 24, 2005
Provisional Application 60547966 · Feb 26, 2004
Related Publication 20110177596A1 · Jul 21, 2011